IAD Index of Academic Documents
  • Home Page
  • About
    • About Izmir Academy Association
    • About IAD Index
    • IAD Team
    • IAD Logos and Links
    • Policies
    • Contact
  • Submit A Journal
  • Submit A Conference
  • Submit Paper/Book
    • Submit a Preprint
    • Submit a Book
  • Contact
  • Dicle Tıp Dergisi
  • Volume:43 Issue:1
  • Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Authors : Durmuş Çetin, Ebubekir Gündeş, Ulaş Aday, Hüseyin Çiyiltepe, Kamuran Değer, Mustafa Duman
Pages : 0-0
Doi:10.5798/diclemedj.0921.2016.01.0661
View : 22 | Download : 11
Publication Date : 2016-03-01
Article Type : Research Paper
Abstract :Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery. Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer
Keywords : Bevacizumab, ince barsak perforasyonu, metastatik kolorektal kanser

ORIGINAL ARTICLE URL
VIEW PAPER (PDF)

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.


Index of Academic Documents
İzmir Academy Association
CopyRight © 2023-2025